Study guide
16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders
Key Takeaways Explain This Topic AI
High-risk HPV types, above all HPV 16, cause cervical, vulval, penile, and anal intraepithelial neoplasia through E6 degradation of p53 and E7 inactivation of the retinoblastoma protein.
The LAST terminology divides HPV-related anogenital squamous lesions into low-grade (LSIL) and high-grade (HSIL) squamous intraepithelial lesions, with block-type p16 staining supporting HSIL.
Differentiated VIN is HPV-independent, arises in lichen sclerosus or lichen planus in older women, and carries a higher risk of invasive cancer than HPV-related vulval HSIL.
The 2022 EU Council Recommendation advises primary HPV testing for cervical screening in women aged 30 to 65 years at intervals of 5 years or more.
The ANCHOR trial showed that treating anal HSIL in people living with HIV reduced progression to anal cancer by 57% compared with active monitoring.
Last updated: September 2026
- 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders
- HPV and Cancer
Low-risk types (mainly HPV 6 and 11 ) cause about 90% of anogenital warts and low-grade lesions.
High-risk types ( HPV 16, 18, 31, 33, 45, 52, 58 , and others) cause cancers of the cervix, vulva, vagina, penis, anus, and oropharynx. HPV 16 is the most important type outside the cervix.
Oncogenesis: the viral oncoprotein E6 targets p53 for degradation, and E7 inactivates the retinoblastoma protein (pRb) . Integration of viral DNA and persistent infection allow progression. Loss of pRb function leads to strong, diffuse ("block-type") p16 staining , a useful marker of HPV-related high-grade disease.
Risk factors for persistence and progression: smoking, HIV and other immunosuppression (including transplant recipients), and many sexual partners.
Terminology
The Lower Anogenital Squamous Terminology (LAST) system uses a two-tier scheme for all HPV-related squamous lesions of the lower anogenital tract:
LAST Category Older Terms Meaning
LSIL (low-grade squamous intraepithelial lesion) CIN 1, AIN 1, VIN 1, flat condyloma Productive HPV infection; often regresses
HSIL (high-grade squamous intraepithelial lesion) CIN 2–3, AIN 2–3, usual-type VIN, PeIN, Bowenoid papulosis , erythroplasia of Queyrat , Bowen disease Precancer with a real risk of invasion
Vulva (ISSVD 2015): vulval LSIL; vulval HSIL (the HPV-related "usual type", in younger women and smokers, often multifocal); and differentiated VIN (dVIN) , which is HPV-independent . dVIN arises in lichen sclerosus or lichen planus in older women, often has TP53 mutations, looks subtle, and has a higher and faster risk of invasive cancer .
Penis: HPV-related penile intraepithelial neoplasia (warty or basaloid; clinically Bowenoid papulosis, erythroplasia of Queyrat, or Bowen disease) versus differentiated PeIN linked to lichen sclerosus.
Cervical Screening and Colposcopy
The 2022 EU Council Recommendation advises primary HPV testing for women aged 30–65 years at intervals of 5 years or more . Younger women (from about 25) may still be screened with cytology in some programmes. Positive HPV tests are triaged with cytology or genotyping.
Colposcopy examines the cervix after acetic acid (abnormal epithelium turns acetowhite ) and sometimes Lugol iodine (abnormal areas do not stain). The transformation zone is where most lesions arise.
Treatment: CIN 1 is usually observed. CIN 2 in young women may be observed with close follow-up. CIN 3 is treated, most often by large loop excision of the transformation zone (LLETZ) . In pregnancy, colposcopy is safe, but treatment is usually deferred until after delivery unless invasion is suspected.
Vulval and Penile HSIL
Lesion Treatment Options Follow-Up
Vulval HSIL Wide local excision; laser ablation; topical imiquimod (off-label, supported by trial evidence) Long-term review; examine cervix and anus as well (field effect)
Differentiated VIN Excision (higher cancer risk) Treat the underlying lichen sclerosus with very potent topical steroids
Penile HSIL / PeIN Topical 5-fluorouracil or imiquimod, laser, excision, glans resurfacing; circumcision Examine partners' cervical screening status
Bowenoid papulosis (multiple small brown papules in young adults) often behaves more benignly than erythroplasia of Queyrat (a solitary velvety red glans plaque in older uncircumcised men), but both are HSIL.
Anal HSIL and Anal Cancer
Highest-risk groups: MSM and transgender women living with HIV , other people with HIV, women with vulval HSIL or cancer, and solid organ transplant recipients.
Screening: anal cytology or HPV testing, and digital anorectal examination, followed by high-resolution anoscopy (HRA) with biopsy. International Anal Neoplasia Society guidance (2024) recommends screening the highest-risk groups, for example MSM and transgender women with HIV from about 35 years.
The ANCHOR trial (2022): in people living with HIV with biopsy-proven anal HSIL, treatment reduced progression to anal cancer by 57% compared with active monitoring.
Treatment: HRA-guided ablation (electrocautery, infrared coagulation) or topical imiquimod or 5-fluorouracil.
HPV Vaccination
The nine-valent vaccine covers types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Most European countries vaccinate both girls and boys , usually from about 9 to 14 years with two doses , with catch-up programmes and targeted vaccination of MSM. Immunocompromised people receive three doses .
Vaccination prevents new infections but does not treat existing lesions. It greatly reduces anogenital warts and cervical precancer in vaccinated populations.
Common Gynaecological Disorders Seen in Dermato-Venereology
Condition Features
Vulvodynia Chronic vulval pain without a visible cause. Provoked vestibulodynia causes pain at the vestibule on touch (cotton-swab test). Diagnosis of exclusion; managed with education, pelvic floor physiotherapy, topical anaesthetics, and neuropathic agents
Vulval dermatoses Lichen sclerosus, lichen planus, lichen simplex chronicus, psoriasis, and irritant or allergic contact dermatitis
Genitourinary syndrome of menopause Dryness, irritation, dyspareunia, and recurrent urinary symptoms from oestrogen deficiency; vaginal oestrogen helps
Bartholin cyst or abscess Painful swelling at the posterolateral introitus; drainage or marsupialisation
Cervical ectropion Red columnar epithelium on the ectocervix; can bleed after sex; exclude infection and neoplasia
Common Andrological Disorders
Condition Features
Pearly penile papules Rows of small skin-coloured papules around the corona; normal variant (angiofibromas), not warts; reassure
Fordyce spots and angiokeratoma of the scrotum (Fordyce) Benign; sebaceous glands and small red-purple vascular papules
Phimosis / paraphimosis Tight foreskin, often from lichen sclerosus; paraphimosis (retracted foreskin that cannot be replaced) is a urological emergency
- Peyronie disease Fibrous plaque of the tunica albuginea causing penile curvature and pain
- Sclerosing lymphangitis and penile Mondor disease Cord-like thickening after vigorous sex; self-limiting
- Epididymo-orchitis and testicular torsion See the genital infection section; torsion is a surgical emergency